Stock IBRX IMMUNITYBIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News ImmunityBio, Inc.

Equities

IBRX

US45256X1037

Real-time Estimate Cboe BZX
Other stock markets
 11:39:33 2024-04-29 am EDT 		5-day change 1st Jan Change
8.465 USD +15.17% Intraday chart for ImmunityBio, Inc. +82.19% +79.28%
05:06pm Piper Sandler Adjusts Price Target on ImmunityBio to $6 From $5, Maintains Neutral Rating MT
12:52pm Social Buzz: Wallstreetbets Stocks Mostly Higher Premarket Monday; Tesla, ImmunityBio to Advance MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Piper Sandler Adjusts Price Target on ImmunityBio to $6 From $5, Maintains Neutral Rating
MT
Social Buzz: Wallstreetbets Stocks Mostly Higher Premarket Monday; Tesla, ImmunityBio to Advance
MT
ImmunityBio : Investor Live Audio Webcast – ANKTIVA Post Approval
PU
Transcript : ImmunityBio, Inc. - Special Call
ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer
AQ
ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer
BU
ImmunityBio, Inc. Announces Positive Overall Survival Results of Anktiva Combined with Checkpoint Inhibitors in Non-Small Cell Lung Cancer
CI
ImmunityBio Announces FDA Approval of ANKTIVA, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
AQ
ImmunityBio Gaining in Tuesday Pre-Market after FDA Approval for Anktiva-Bacterium Combination for Bladder Cancer
MT
Upcoming Big Tech Earnings Buoy Exchange-Traded Funds, Equity Futures Pre-Bell Tuesday
MT
Top Premarket Gainers
MT
ImmunityBio Shares Soar Premarket on FDA Nod for Anktiva
DJ
US FDA approves ImmunityBio's bladder cancer therapy
RE
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
BU
ImmunityBio, Inc. Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
CI
U.S. FDA approves ImmunityBio's bladder cancer therapy
RE
ImmunityBio Files Mixed Shelf
MT
North American Morning Briefing : Markets Steady -2-
DJ
Piper Sandler Adjusts Price Target on ImmunityBio to $5 From $4, Maintains Neutral Rating
MT
ImmunityBio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IBRX Stock
  4. News ImmunityBio, Inc.